@article{APS5393,
author = {Qiong Huang and Ji-ye Yin and Xing-ping Dai and Qi Pei and Min Dong and Zhi-guang Zhou and Xi Huang and Min Yu and Hong-hao Zhou and Zhao-qian Liu},
title = {IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population},
journal = {Acta Pharmacologica Sinica},
volume = {31},
number = {6},
year = {2016},
keywords = {},
abstract = {Aim: To investigate whether the insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs1470579 and rs4402960 polymorphisms are associated with the development of type 2 diabetes mellitus (T2DM) and the repaglinide therapeutic efficacy in Chinese T2DM patients.
Methods: A case-control study of a total of 350 patients with T2DM and 207 healthy volunteers was conducted to identify their genotypes for the IGF2BP2 rs1470579 and rs4402960 polymorphisms using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Forty-two patients were randomly selected to undergo an 8-week repaglinide treatment (3 mg/d). Fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin (HbAlc), fasting serum insulin (FINS), postprandial serum insulin (PINS), homeostasis model assessment for insulin resistance (HOMA-IR), serum triglyceride, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), and high-density lipoprotein-cholesterol (HDL-c) were determined before and after repaglinide treatment.
Results: The frequencies of the IGF2BP2 rs1470579 C allele and the rs4402960 T allele were higher in T2DM patients than in healthy controls (P},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/5393}
}